Evotec SE stock (DE0005664809): Q1 2026 results show sharp revenue drop amid restructuring

Evotec SE reported a 21.7% year?on?year revenue decline in the first quarter of 2026 as one?off restructuring costs and weaker demand weighed on earnings, even as the company advances a major strategic overhaul.

Evotec SE posted a steep 21.7% year?on?year revenue decline in the first quarter of 2026, driven by a large one?off restructuring charge and softer demand in its Discovery & Preclinical Development segment, according to a recent earnings summary based on the company’s Q1 2026 results presentation and related coverage.StockTitan as of 05/06/2026

Group revenue fell to €156.6 million in Q1 2026, with both the Discovery & Preclinical Development and Just – Evotec Biologics segments posting negative adjusted EBITDA, as the prior?year quarter had benefited from a sizable Sandoz license payment and demand in early?stage discovery remained weak.StockTitan as of 05/06/2026

Despite the sharp downturn in profitability, Evotec highlighted that liquidity and cash flow remained solid, underpinning its ability to continue funding the ongoing restructuring and strategic review, which includes reducing its global footprint from 14 sites to 10 and aiming to increase its win rate on new projects.StockTitan as of 05/06/2026

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Evotec SE
• Sector/industry: Life sciences / drug discovery and development
• Headquarters/country: Hamburg, Germany
• Core markets: Global pharmaceutical and biotech partners
• Key revenue drivers: Discovery & Preclinical Development services, biologics platform (Just – Evotec Biologics)
• Home exchange/listing venue: XETRA (EVT), NASDAQ (EVO ADR)
• Trading currency: EUR (home), USD (ADR)

Evotec SE: core business model

Evotec SE operates as a global life?science company focused on drug discovery and development, providing integrated research and development services to pharmaceutical and biotechnology firms.Evotec corporate site

The company combines proprietary platforms in areas such as RNA?based therapeutics and biologics with contract research and development programs, helping partners identify and optimize new drug candidates across multiple therapeutic areas.Evotec corporate site

Evotec’s business model centers on long?term partnerships and milestone?driven contracts, with revenue streams from discovery services, preclinical development, and biologics manufacturing through its Just – Evotec Biologics unit.Evotec corporate site

Main revenue and product drivers for Evotec SE

Discovery & Preclinical Development is Evotec’s largest segment, generating revenue from early?stage drug discovery projects, target identification, and preclinical testing for external partners.StockTitan as of 05/06/2026

The Just – Evotec Biologics platform contributes through biologics discovery, development, and manufacturing services, including antibody and protein?based therapeutics, which are increasingly important in oncology and immunology pipelines.Evotec corporate site

Recent project milestones, such as the nomination of a first preclinical development candidate in a dermatology collaboration with Almirall, illustrate how new program starts and clinical?stage transitions can support future revenue and milestone income, even as current?period demand remains volatile.BioSpace as of 04/29/2026

Why Evotec SE matters for US investors

US investors encounter Evotec SE primarily through its American depositary receipts listed on NASDAQ under the ticker EVO, giving exposure to a European?based life?science services provider with a global client base.Morningstar as of 05/08/2026

The company’s partnerships with large pharmaceutical and biotech firms, including collaborations in areas such as dermatology and infectious diseases, tie its performance to broader trends in R&D spending and outsourcing in the US?centric biopharma sector.BioSpace as of 04/29/2026

For US?based portfolios, Evotec SE offers a leveraged play on drug discovery outsourcing and biologics development, but also carries currency, regulatory, and execution risks associated with a mid?sized European biotech services firm undergoing a strategic transformation.StockTitan as of 05/06/2026

Conclusion

Evotec SE’s first?quarter 2026 results highlight a challenging operating environment, with a 21.7% revenue drop and negative adjusted EBITDA in both main segments, even as the company maintains solid liquidity and advances a major restructuring and strategic review.StockTitan as of 05/06/2026

The planned reduction of its global footprint and focus on improving win rates on new projects could position the company for more sustainable growth over the medium term, but execution risk and continued volatility in discovery demand remain key concerns.StockTitan as of 05/06/2026

For US investors, Evotec SE offers exposure to global drug discovery and biologics outsourcing, but the stock’s performance will depend heavily on the success of its turnaround plan, the stability of partner R&D budgets, and broader macroeconomic conditions affecting biopharma spending.Morningstar as of 05/08/2026

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.